NRx Pharmaceuticals receives FDA clearance for depression trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression an
May 7, 2026 8:00 AM EDTPreliminary research suggests that D-cycloserine significantly enhances the effect of Transcranial Magnetic Stimulation (TMS) Trial is planned to be conducted at a leading US academic teaching hospital, three HOPE Therapeutics Clinics, and two military treatment facilitiesCompany targeting non-dilutive funding to support enrollment of 400 patients Should the trial yield successful results, D-cycloserine-augmented TMS could play a significant role in the readiness of first responders, military personnel, and others affected by Treatment-resistant Depression
WILMINGTON, Del., May 07, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq:... More
